|
Volume 270,
Number 49,
Issue of December 8, 1995 pp. 29594-29600
©1995 by The American Society for Biochemistry and Molecular Biology, Inc.
The Plasmacytoma
Growth Inhibitor Restrictin-P Is an Antagonist of Interleukin 6 and
Interleukin 11
IDENTIFICATION AS A STROMA-DERIVED ACTIVIN A
(Received for publication, August 25, 1995; and in revised form, September 27, 1995)
Naama
Brosh
,
Dalia
Sternberg
,
Judy
Honigwachs-Sha'anani
,
Byeong-Chel
Lee
,
Yaron
Shav-Tal
,
Esther
Tzehoval
,
Lester
M.
Shulman
,
Jeky
Toledo
,
Yael
Hacham
,
Pnina
Carmi
,
Wen
Jiang
,
Jurgen
Sasse
,
Friedemann
Horn
,
Yigal
Burstein
,
Dov
Zipori
A stromal protein, designated restrictin-P, that specifically
kills plasma-like cells was purified to homogeneity and shown to be
identical with activin A. The specificity to plasma-like cells stemmed
from the ability of restrictin-P/activin A to competitively antagonize
the proliferation-inducing effects of interleukin (IL) 6 and IL-11.
Restrictin-P further interfered with the IL-6-induced secretion of
acute phase proteins by HepG2 human hepatoma cells and with the
IL-6-mediated differentiation of M1 myeloblasts. A competition binding
assay indicated that restrictin-P did not interfere with the binding of
IL-6 to its receptor on plasma-like cells, suggesting that it may act
by intervening in the signal transduction pathway of the growth factor.
Indeed, concomitant addition of restrictin-P and IL-6 to
cytokine-deprived B9 hybridoma cells was followed by sustained
overexpression of junB gene until cell death occurred, while
IL-6 alone caused a transient increase only. This altered response to
IL-6 stimulation was accompanied by a moderate increase in STAT protein
activation. Thus, in this study, we identified the plasmacytoma growth
inhibitor, restrictin-P, as being activin A of stromal origin. It is
shown that activin A is an antagonist of IL-6-induced functions and
that it modifies the IL-6 signaling pattern.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
A. Lacerte, E.-H. Lee, R. Reynaud, L. Canaff, C. de Guise, D. Devost, S. Ali, G. N. Hendy, and J.-J. Lebrun
Activin Inhibits Pituitary Prolactin Expression and Cell Growth through Smads, Pit-1 and Menin
Mol. Endocrinol.,
June 1, 2004;
18(6):
1558 - 1569.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. W. Brown, L. Li, D. E. Houston-Hawkins, and M. M. Matzuk
Activins Are Critical Modulators of Growth and Survival
Mol. Endocrinol.,
December 1, 2003;
17(12):
2404 - 2417.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. A. Harrison, P. C. Gray, S. C. Koerber, W. Fischer, and W. Vale
Identification of a Functional Binding Site for Activin on the Type I Receptor ALK4
J. Biol. Chem.,
May 30, 2003;
278(23):
21129 - 21135.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Shav-Tal and D. Zipori
The Role of Activin A in Regulation of Hemopoiesis
Stem Cells,
November 1, 2002;
20(6):
493 - 500.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Shoham, E. Yaniv, R. Koren, R. Gal, R. Parameswaran, A. Kravitz, H. Geron, D. Markovitz, M. Lantzki, and D. Zipori
Reduced Expression of Activin A in Focal Lymphoid Agglomerates Within Nasal Polyps
J. Histochem. Cytochem.,
October 1, 2001;
49(10):
1245 - 1252.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Zipori and M. Barda-Saad
Role of activin A in negative regulation of normal and tumor B lymphocytes
J. Leukoc. Biol.,
June 1, 2001;
69(6):
867 - 873.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O. Hjertner, H. Hjorth-Hansen, M. Borset, C. Seidel, A. Waage, and A. Sundan
Bone morphogenetic protein-4 inhibits proliferation and induces apoptosis of multiple myeloma cells
Blood,
January 15, 2001;
97(2):
516 - 522.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. L. Lau, T. R. Kumar, K. Nishimori, J. Bonadio, and M. M. Matzuk
Activin beta C and beta E Genes Are Not Essential for Mouse Liver Growth, Differentiation, and Regeneration
Mol. Cell. Biol.,
August 15, 2000;
20(16):
6127 - 6137.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
K. Kitamura, S.-i. Aota, R. Sakamoto, S.-I. Yoshikawa, and K. Okazaki
Smad7 selectively interferes with different pathways of activin signaling and inhibits erythroid leukemia cell differentiation
Blood,
June 1, 2000;
95(11):
3371 - 3379.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Yamato, T. Koseki, M. Ohguchi, M. Kizaki, Y. Ikeda, and T. Nishihara
Activin A Induction of Cell-Cycle Arrest Involves Modulation of Cyclin D2 and p21CIP1/WAF1 in Plasmacytic Cells
Mol. Endocrinol.,
July 1, 1997;
11(8):
1044 - 1052.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
X. Du and D. A. Williams
Interleukin-11: Review of Molecular, Cell Biology, and Clinical Use
Blood,
June 1, 1997;
89(11):
3897 - 3908.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Zauberman, S. Lapter, and D. Zipori
Smad Proteins Suppress CCAAT/Enhancer-binding Protein (C/EBP) beta - and STAT3-mediated Transcriptional Activation of the Haptoglobin Promoter
J. Biol. Chem.,
June 29, 2001;
276(27):
24719 - 24725.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1995 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|